Nektar Therapeutics
NASDAQNektar Therapeutics heads into its May 7 first-quarter report carrying two compounding weights: a flurry of securities fraud class actions and a 10.7% weekly price decline that has tested the conviction of a Street that only recently turned bullish on the stock. The lawsuit angle dominates the news flow this week. Multiple law firms — Rosen, Faruqi & Faruqi, Pomerantz, Levi &…
Snapshot as of 9 May 2026
Nektar Therapeutics heads into its May 7 first-quarter report carrying two compounding weights: a flurry of securities fraud class actions and a 10.7% weekly price decline that has tested the conviction of a Street…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for NKTR — free to start on ORTEX.
Sign up for free →Open NKTR on ORTEX